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The  Serum  Bactericidal  Antibody  assay  with  human  complement  (hSBA)  using  individual  immune  sera  is  a
surrogate  of  protection  for meningococcal  vaccines.  Strain  coverage  of 4CMenB,  a licensed  vaccine  against
serogroup  B meningococcal  (MenB)  disease,  has  been  extensively  assessed  in hSBA  using  pooled  sera,
directly or  through  the Meningococcal  Antigen  Typing  System  (MATS).  The  extent  to  which  pooled-sera
hSBA  titres  reﬂect  individual  protection  is not  yet  fully  understood.
We  analysed  more  than  17000  individual  hSBA  titres  from  infants  and  toddlers  vaccinated  with
4CMenB,  pooled-serum  hSBA  titres  from  subsets  therein  and MATS  data  from  a 40  strain  panel  rep-
resentative  of invasive  MenB  disease  in  England  and  Wales.
Individual  hSBA  titres  segregated  in  two  normal  distributions,  respectively  from  responding  and non-
responding  subjects  (ﬁt model-data:  r  =  0.996,  p-values  <0.05).  No  individual  subject  showed  abnormally
high  titres  compared  to  the  distributions.  Also,  when  sera  from  the  same  subjects  were  tested  individually
and  in  pool,  pooled-sera  titre and  average  of individual  titres from  the  same  group  were  substantially
indistinguishable  (r = 0.97,  p-value  «0.001).
We  identiﬁed  a robust  mathematical  relationship  between  the  mean  of individual  hSBA  titres  and  the
proportion  of  subjects  achieving  a protective  titre  (seroprotection  rate,  r  = 0.95,  p-value  «0.001).  Using
this  relation,  the  seroprotection  rate  in  15  groups  of  vaccinees  tested  against  11  diverse  meningococcal
isolates  was  accurately  predicted  by the hSBA  titre  of  the  respective  pooled  sera (average  prediction  error
9%).
Finally, strains  deﬁned  covered  by  MATS  had  on  average  77%  predicted  seroprotection  rate  (interquar-
tile  range,  IQR:  66–100%)  and  39% for non-covered  strains  (IQR:  19–46%).We conclude  that  seroprotection  rates  in  infants  and toddlers  vaccinated  with  4CMenB  can  be  accu-
rately  predicted  by pooled-serum  hSBA,  and that  strain  coverage  deﬁned  by MATS  is  associated  with  high
seroprotection  rates.
Summary:  The  Serum  Bactericidal  Antibody  assay  (SBA)  from  individual  sera  is a  surrogate  of  protection
for  meningococcal  vaccines.  We  show  that SBA  performed  on  pooled  sera  predicts  individual  protection.
ublis© 2016  The  Authors.  P
. Introduction
Neisseria meningitidis, a gram-negative bacterium classiﬁed into
2 serogroups on the basis of their polysaccharide capsule causes
ore than 120,0000 cases of invasive meningococcal disease (IMD)
er year [1]. Serogroup B N. meningitidis (MenB) is the lead-
ng cause of IMD  in developed countries [2,3]. A genome-based
pproach, reverse vaccinology [4], was applied to develop the
∗ Corresponding author.
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license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
recently approved, protein-based four-component 4CMenB vac-
cine [5] against MenB disease [6–8].
The impact of a protein-based vaccine on IMD will largely
depend on both the proportion of subjects mounting a protective
immune response (the “seroprotection rate”) and the proportion
of MenB strains susceptible to the response elicited (”strain cover-
age”).
The Serum Bactericidal Antibody assay with human comple-
ment (hSBA, [9]) is accepted as a surrogate of protection in the
clinical evaluation of meningococcal vaccines [10,11]. The relation-
ship between seroprotection and protection from IMD  should be
further clariﬁed for 4CMenB by UK’s national immunisation cam-
paign started in September 2015. The result of the assay is a titre,
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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.e. the number of times a serum can be diluted and still remains
apable of killing the cells of the bacterium.
The plasticity of the meningococcal genome facilitates the adap-
ation of surface structures to changing environments through a
ariety of genetic mechanisms [12]. These result in a high variabil-
ty of sequence and level of surface expression for 4CMenB antigens,
ffecting strain susceptibility to vaccine-induced antibodies.
Using hSBA to evaluate the potential effectiveness of protein-
ased vaccines would require testing the serum of many subjects
gainst many different isolates – an arduous undertaking because
f the time required and of serum limitations, especially for infants.
Multiple individual sera can be pooled to reduce the experimen-
al workload, by testing strains in pooled-sera hSBA to determine
accine strain coverage. A further simpliﬁcation was  provided by
 novel assay that does not require the use of human serum,
he Meningococcal Antigen Typing System (MATS) [13,14]. MATS,
eveloped to facilitate studies of large strain panels, was shown to
ccurately predict pooled-sera hSBA results [15].
Both the pooled-sera hSBA and the MATS used to determine
CMenB strain coverage [16–18] are based on the assumption
hat pooled sera, obtained by mixing equal amounts of sera from
ndividual subjects in randomized controlled clinical trials, ade-
uately reﬂect the average response to vaccination of the individual
ubjects in the group. This assumption was never conﬁrmed experi-
entally, and could be violated by highly heterogeneous individual
mmune responses in the pool and/or synergistic effects among
ub-bactericidal antibody levels in different subjects.
To verify the signiﬁcance of pooled sera as indicators of individ-
al responses to vaccination with 4CMenB, here we  analysed two
istinct hSBA datasets: i) 16858 titres from 5250 infants and tod-
lers vaccinated with 4CMenB in late-stage clinical trials against
even MenB strains [19,20] and ii) matched individual and pooled-
era hSBAs from 431 infant and toddler vaccinees, generated in the
resent study against 11 MenB strains expressing different combi-
ations of high, medium and low amounts of 4CMenB antigens.
To substantiate the validity of the 4CMenB strain coverage
redictions, on which basis the vaccine was approved for use in
umans, results were applied to a third dataset of pooled-sera
SBA and MATS data from a panel of 40 isolates representative of
erogroup B IMD  in England and Wales [15].
. Materials and methods
.1. hSBA assays
The Serum Bactericidal Antibody assay with human comple-
ent (hSBA) was performed as previously described (see [9] and
upplemental Materials and methods).
The assay generating interpolated titres was validated for the
ajority of strains, and the interpolated titre value of 5 was shown
o provide 95% conﬁdence of exceeding the value of 4, the estab-
ished correlate of protection for IMD  [10]. Five was considered the
rotective hSBA threshold in all analyses.
.2. Datasets
Three datasets were used in the present study: 1) and 3) from
revious studies, 2) newly generated here.
) Classiﬁcation of individual hSBA titres into 86 groups. 16858
hSBA titres against 7 MenB strains from sera of infants and
toddlers immunized with 4CMenB in late-stage clinical stud-
ies [19,20] were classiﬁed in groups for subsequent analysis as
follows: titres from i) subjects immunized with the same immu-
nization schedule, ii) in the same study, iii) tested at the same4 (2016) 2579–2584
schedule-timepoint, iv) against the same strain, were grouped.
Eighty-six groups were deﬁned, with group sizes varying from
16 to 558 (see Table S1).
2) Paired individual and pooled-sera hSBA titres. Newly generated
hSBA results from 431 infant and toddler sera, banked from a
Phase 3 clinical trial [20], were tested both individually and in
pools against 11 MenB strains. Each pool was  composed of sera
from 30 randomly selected subjects and hSBA tests were per-
formed on blood draws taken 1 and 6 months post-3rd dose. As
summarized in Table S2, MenB strains were purposely selected
to represent low, medium and high MATS relative potencies for
the 4CMenB antigens, both in isolation and in combination, and
diverse antigenic genotypes.
3) Matched pooled-sera hSBA titres and MATS data from 40
MenB isolates representative of IMD  in England and Wales in
2007−2008 [15] (Table S3).
2.3. Mathematical model for hSBA titre density
For each group i in Table S1, the density distribution of log2
individual hSBA titres have been described by a mixture fi of two
gaussian distributions:
fi(x) = (1 − wi) · No(0,  0) + wi · N1(i, i) (1)
where x is the discretized log2 hSBA titre, No is the positive half of a
Gaussian distribution centred at zero with the standard deviation
0 = log2(5)/3, N1 is a positively deﬁned Gaussian distribution with
mean i and standard deviation i, and wi is the relative weight of
N1 to No in the mixture fi (further details in supplemental Materials
and methods).
2.4. Functional relationship between arithmetic mean of
individual titres and rate of protection
Given the arithmetic mean titre x of a group, the correspondent
seroprotection rate (SR) was predicted with the logistic function:
SR =
(
1 + exp
(
b
(
log
(
x
e
))))−f
(2)
with minimum 0%, maximum 100%, b, e, and f as free parameters.
2.5. Statistical analyses
Non-linear regressions of Eqs. (1) and (2) to data were obtained
by the least-squares method as implemented in the nls and drc
packages of R version 3.0.2 (http://www.r-project.org/).
Goodness of ﬁt for each model was  quantiﬁed by the Pearson
correlation coefﬁcient r between raw and ﬁtted data, as imple-
mented in the function cor.test() of R version 3.0.2.
The precision of prediction for each mathematical model was
measured by the Mean Absolute prediction Error (MAE [21]).
3. Results
3.1. Individual titres from responding and non-responding
subjects are described by two distinct normal distributions,
respectively
Nine of the 86 groups of subjects in dataset 1 (Table S1) had
seroprotection rates (i.e. the proportion of subjects with an hSBA
titre ≥ 5, see Materials and methods) ≤20%, 17 groups between 20
and 80%, and 60 groups responded >80%.Fig. 1 shows the distribution of log2 hSBA titres for three typical
groups of vaccinees with different seroprotection rates, with titres
from non-responding subjects coloured in red and from responders
in blue.
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Fig. 1. Distributions of individual hSBA titres. Shown, as histograms for three typical groups of subjects with different seroprotection rates (SR: 12% (A), 47% (B) and 99% (C) -
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jects composing each pool generated in this study from dataset 2
(see Materials and methods and Table S2).
Each of the 13 measurable pooled-sera titres (≥2) matched
closely the mean of the corresponding individual hSBA titresn  Table S1 respectively group 25, 48, and 79), is the proportion of subjects having
f  each histogram’s bar. The dashed line marks the protective titre threshold of 5. 
ndicate the best ﬁt to data of No (red) and N1 (blu) components in Eq. (1).
In each of the 86 groups (Fig. S1), titres from responding subjects
ere always clustered around a single value, and bell-shape dis-
ributed. The density of titres from non-responding subjects peaked
t zero and rapidly decreased towards the titre of value 5.
This behaviour of the hSBA titre density in each group i can be
escribed mathematically by a mixture fi of two truncated Gauss-
an distributions No and N1 (red and blue respectively in Fig. 1) as
escribed in Eq. (1).
N1 describes hSBA titres from responding subjects, and in each
roup it can have a different mean, standard deviation and weight.
o describes hSBA titres from non-responders, is always centred
t zero and has a ﬁxed standard deviation such that >99% of the
ensity corresponds to titres <5.
In each group, we determined the best ﬁt of Eq. (1) to data. In
2 of the 86 groups, we estimated all parameters for No and N1.
he remaining four subject groups were ﬁtted only with the No
omponent of Eq. (1) due to the absence of responders.
Eq. (1) accurately described the experimental distributions of
SBA titres in all groups (median correlation raw − ﬁtted data 0.996,
ange @95%: 0.75–1.00, all p-values <0.05, see Figs. S1 and S2). The
verage across groups for the standard deviation  was  1.14 (range
95%: 0.75–1.74, Fig. S3C), i.e. approximately one step-2 dilution,
ndicating a compact distribution of the hSBA titres around the
ean value.
Comparison between mathematical parameters in Eq. (1) and
heir serological meaning (see Fig. S3) conﬁrmed that, in all groups
f subjects analysed: i) titres from responding and non-responding
ubjects can be modelled separately, ii) titres from responding sub-
ects are clustered around a well-deﬁned mean-value, iii) no highly
eterogeneous individual immune responses were observed.
.2. The arithmetic mean of individual hSBA titres predicts the
roportion of responders
Fig. 2 shows, for each group of subjects listed in Table S1, the
ercentage of individuals with an hSBA titre ≥ 5 (seroprotection
ate), versus the arithmetic mean of the same titres. When the mean
itre lies approximately between 2 and 64, the seroprotection rate
rows proportionally. When the mean is greater than 64 or lower
han 2, the seroprotection rate approaches 100 and 0%, respectively.SBA titre comprised between the lower (included) and the upper (excluded) limit
esponders and responders are red and blue-shaded, respectively. The solid curves
Overall, the logistic function of the arithmetic mean of the hSBA
titres described in Eq. (2) predicted accurately the seroprotection
rate (correlation raw-ﬁtted data r = 0.95, p-value «0.001). Fig. S4
shows the comparison between predicted and measured seropro-
tection rate. A MAE  of 5% (range @95%: 0.0−21%) and an absolute
bias of 0.9% indicated consistent precision and accuracy for the pre-
diction. In summary, results indicated that Eq. (2) is a mathematical
relationship that can be used to accurately predict the seroprotec-
tion rate of a group of vaccinees from the average of their individual
hSBA titres.
3.3. Pooled-sera hSBA titres correspond to the arithmetic mean of
the titres from individual sera composing the pool
Fig. 3 shows hSBA titres from both pools and the individual sub-Fig. 2. Relationship between seroprotection rate and average of individual hSBA
titres. The seroprotection rate (% of subjects with hSBA titres ≥5) vs. the arithmetic
mean of all hSBA titres is shown for each of the 86 groups of vaccinees. The continu-
ous red curve is the best least-square ﬁt of Eq. (2) to data, obtained for b = −2.8841,
e  = 21.9464 and f = 0.3986. Dashed red curves represent the 95% prediction interval.
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Fig. 3. Relationship between pooled-sera titres and arithmetic mean of individual
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Fig. 5. Predicted seroprotection by MATS coverage in England and Wales. Boxplot
of  seroprotection rates for 40 strains representative of IMD  in England and Wales,
predicted from pooled-sera hSBA titres through Eq. (3). Left: 12 strains predicted
not-covered by MATS. Right: 28 strains predicted covered by MATS. The Box plots
indicate The central box represents half of the covered/not-covered strains withitres. Pooled-sera hSBA titres vs. arithmetic mean of individual titres from subjects
omposing the pool, for the 15 groups of subjects described in Table S2.
Fig. 3). In two groups, the non-measurable pooled-sera titre (<2)
lightly underestimated the average individual responses which,
owever, remained below the seroprotection threshold (< 5). Over-
ll, the measurable pooled-sera titres corresponded to the mean of
he titres composing the pool with a correlation of r = 0.97 (p-value
0.001) and a MAE  of 1.4%, indicating lack of measurable synergistic
ffects among sub-bactericidal antibody levels in different subjects.
.4. Pooled-sera hSBA titres predict the proportion of individuals
rotected from disease
Having observed i) a robust mathematical relationship between
eroprotection rate and mean individual titres (Eq. (2)) and ii) a sub-
tantial identity between mean individual and pooled-sera titres
Fig. 3), we used Eq. (2) to correlate pooled-sera hSBA titres and
eroprotection rate.
ig. 4. Relationship between pooled-sera hSBA titres and seroprotection rate.
ooled-sera hSBA titres vs. seroprotection (percentage of sera composing the pool
ith hSBA titre ≥5) for the 15 groups of subjects described in Table S2. The solid
ed line is the best ﬁt of Eq. (2) to data. Dashed lines are the 95% conﬁdence interval
black) and the 95% prediction interval (red).whiskers representing the upper (75%) and lower quartiles (25%) of strains. The
median predicted seroprotection rates is indicated by the thick line. The whiskers
above and below the box show the locations of the minimum and maximum.
Fig. 4 shows, for the all the subjects analysed in dataset 2 (see
Materials and methods and Table S2), the seroprotection rate vs.
the pooled-sera hSBA titre. The solid red curve shows the best ﬁt of
Eq. (2) to experimental data:
SR =
(
1 + exp
(
−17.977
(
log
(
x
27.897
))))−0.042
(3)
were SR is the seroprotection rate for a group of subjects vs.  a given
strain at a given timepoint, and x is the corresponding pooled-sera
titre.
Despite the limited number of individual sera composing each
pool, results indicate that Eq. (3) describes adequately the direct
relationship between individual and pooled-sera hSBA titres (raw-
ﬁtted data correlation r = 0.94, p-value «0.001). The shaded area in
the graph indicates the 95% regression conﬁdence interval, corre-
sponding to a MAE  of 9% (min−max: 0.0−23%) and absolute bias of
-0.7%. Albeit slightly larger than the precision of arithmetic mean
titre vs. seroprotection rate – due to the smaller size of dataset 2 vs.
dataset 1 – these values conﬁrm that the proportion of infants and
toddlers reaching seroprotection in a group receiving the 4CMenB
vaccine can be reliably predicted by the hSBA titer of the group
pooled-serum.
3.5. MATS coverage is associated with high predicted
seroprotection
We  applied Eq. (3) to predict seroprotection rates for each strain
in dataset 3 (see Table S3), a panel of 40 strains representative of
serogroup B IMD  in England and Wales. Pooled-sera hSBA titres
from infant vaccinees (hSBA strain coverage 88%, CI@95%: 72–95%)
and MATS values (MATS strain coverage 70%, CI@95%: 55–85%)
were previously determined [15].
Fig. 5 shows the distribution of predicted seroprotection rates
against strains deemed covered and those not covered by MATS. The
predicted average seroprotection rate was 77% [IQR: 66–100%] and
39% [IQR: 19–46%] for strains covered and not-covered in MATS,
respectively, corresponding to an overall predicted seroprotection
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f 65% [IRQ: 39–100%], a value similar to the strain coverage pre-
icted by MATS.
. Discussion
The Serum Bactericidal Antibody assay with human comple-
ent (hSBA) from pooled sera has been used, directly or through
he MATS assay, to support the development and strain cover-
ge estimation of the 4CMenB vaccine [13,15,16,22]. The use of
ooled-sera titres was motivated by the observation that antibod-
es contained in individual sera, once pooled, are mutually diluted
n the overall solution. As in any proportional dilution process, the
itre of the pooled serum is expected to be the average of the indi-
idual titres from subjects composing the pool and to reﬂect the
typical” response to vaccination of the individual subjects in the
roup.
However, two effects could violate this assumption. First, if
 minority of subjects in a group of vaccinees mounted a very
igh response, while all others mounted no response at all, the
ool may  still have some measurable killing activity, leading to
n overestimation of the proportion of subjects protected from
isease. Second, sub-bactericidal levels of antibodies in different
ubjects, binding the same or different antigens, could synergisti-
ally contribute to killing in the pool not reﬂecting actual individual
rotection [23–25].
Here, we have re-analysed a broad database of individual hSBA
esults collected in late stage 4CMenB clinical studies, observ-
ng that the individual hSBA responses to 4CMenB were always
istributed according to a regular pattern. Irrespective of the mag-
itude of titres measured, strain tested, number of doses and size
f the group investigated, titres were always clustered in two  dis-
inct components, above and below the protective threshold of
, where titre frequency was always at its minimum, i.e. subjects
arely mounted a response “at threshold”.
Titres from responding subjects were always compactly dis-
ributed around their log2 hSBA mean with spread comparable to
ssay variability, and this mean was proportional to the seroprotec-
ion rate. In other words, when a few subjects mounted a protective
esponse, their hSBA titres were low and close to the immunogenic-
ty threshold; when many subjects responded to vaccination, their
ndividual titres were all high.
A consequence of this regular behaviour is that the arithmetic
ean of all hSBA titres in a group of vaccinees (responding or not
esponding to vaccination) was mathematically linked to the pro-
ortion of subjects mounting a protective titre, explaining why
ooled sera can be used to predict seroprotection.
Results indicate that, when sera from infants and toddlers vac-
inated with 4CMenB are pooled, synergistic effects previously
roposed [25] across adult subjects do not reach a level to sig-
iﬁcantly alter the pool-average relationship. Eleven MenB strains
xpressing variable amounts and combinations of vaccine antigens
ere used for this analysis, one of which had a similar antigenic
ssortment to the strain reported in Vu et al. [25] (fHbp variant
.19 and NHBA medium expression). In our data, the lack of syner-
istic effects was clear, with only one deviation observed below the
imit of detection, but in the opposite direction to that proposed:
he pool titre (<2) was slightly lower than the mean of the corre-
ponding individual titres (4.1–4.7). The different age groups could
asily explain the apparent discrepancy between the two  studies, as
re-existing immunity due to carriage of meningococci in older age
roups can expand the antibody repertoire compared to younger
ubjects [26].
Taken together, the homogeneity of individual responses and
he lack of signiﬁcant synergy in pooled sera justify the high quality
f the mathematical relationship between pooled-sera hSBA titres4 (2016) 2579–2584 2583
and seroprotection derived in Eq. (3) (r = 0.94, p-value «0.001),
although the relatively small sample size investigated (30 subjects
per strain per visit) led to sizable prediction intervals. Direct
application of this relationship to a panel of isolates representative
of MenB IMD  in England and Wales, previously tested in MATS
and pooled-sera hSBA, predicted high rates of seroprotection for
MATS-covered isolates (IQR 66−100%), and non-negligible sero-
protection also for isolates not covered by MATS (IQR 19−46%),
further supporting the use of MATS as a conservative tool to predict
and monitor the impact of 4CMenB on IMD [27].
Even if an individual strain considered as “covered” may  still
cause disease in some vaccinated subjects – MATS coverage thresh-
olds were deﬁned to predict pooled-sera hSBA titres ≥ 8 [13],
associated with ∼40% of protection based on Eq. (3) – when strain
collections representative of the real circulating disease are ana-
lysed, the overall results are robust and consistent.
Limitations of the present study include the number of sub-
jects that could be tested in matched individual-pools. A much
larger study would be necessary to extend the sample size, given
the signiﬁcant volume of infant serum required and the logistic
requirements of the assay. Also, a single surrogate of protection
was analysed here (hSBA), and only in infants and toddlers.
Interestingly, the predictive function identiﬁed here was valid
both for pre- and post-booster timepoints in toddlers, but it is not
obvious how these results would translate to older age groups,
such as adolescents and adults, where baseline immunity induced
by natural exposure and broader antibody repertoire could act as
confounding factors.
As the 4CMenB vaccine was licensed based on the hSBA as a
surrogate for protection, there is no direct evidence yet of its pro-
tective efﬁcacy. The vaccine is being rolled out as part of the UK’s
national infant immunisation programme, which should in due
course provide evidence of its effectiveness. We  believe that the
results presented in this study provide a useful hypothesis to be ver-
iﬁed prospectively in the context of the 4CMenB implementation
programs, when the validity of pooled hSBA and MATS as assays
predicting protection and vaccine antigen coverage respectively
could be unambiguously assessed.
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